|
|
Treatment Algorithm 2002: Hepatitis B and CPublished by: Datamonitor Published: Apr. 29, 2002 - 251 Pages Table of ContentsEXECUTIVE SUMMARY Scope Datamonitor Insight into the Hepatitis Market Non-pegylated interferon monotherapy currently dominates Hepatitis B (HBV) treatment across the major markets, but is superceded by use of lamivudine in second line therapy. In the US and Europe, combination therapy with interferon and ribavirin dominates the hepatitis C (HCV) treatment market - alternative medicine is predominantly used for HCV treatment in Japan. However, rising on and off label usage of pegylated interferons demonstrates the market potential for new drugs A lack of guidelines is creating a marked variation in treatment practice across the seven major markets, as well as fueling physician dissatisfaction with current therapeutic options for chronic hepatitis, presenting an opportunity for new drug developers to target niche segments of the population Despite implementation of infant immunization programs in many countries, the numbers of chronic HBV patients requiring treatment in the developed world will continue to rise until approximately 2020 As patient pressure grows to find an effective cure for HCV, the focus of the treatment market will shift from interferon treatment to antiviral combination therapy, potentially integrated with HAART for HIV coinfected patients. A decrease in the transmission rates of HCV infection will restrict the market for a prophylactic vaccine, focusing research on therapeutic vaccine development Key Metrics INTRODUCTION Scope Structure CLINICAL OVERVIEW Introduction Hepatitis B Disease Overview Epidemiology Current Approaches to Treatment Hepatitis C Disease Overview Epidemiology Current Approaches to Treatment PRESENTATION, SCREENING AND DIAGNOSIS Introduction Hepatitis B Physician Involvment Screening Diagnosis Hepatitis C Physician Involvment Screening Diagnosis GLOBAL AND COUNTRY SPECIFIC TREATMENT PATTERNS Introduction Seven Country Comparison of HBV Therapy First Line Treatment Dosage and Treatment Length Response Rates Relapse Rate Second Line Treatment Treatment Outcome Perception Seven Country Comparison of HCV Treatment First Line Treatment Dosage and Treatment Length Response Rates Relapse Rates Second Line Treatment Treatment Outcome COUNTRY TREATMENT ANALYSIS Treatment in the US - HBV First Line Treatment Second Line Treatment Treatment Outcome Treatment in the US - HCV First Line Treatment Second Line Treatment Treatment Outcome Treatment in Japan - HBV First Line Treatment Second Line Treatment Treatment Outcome Treatment in Japan - HCV First Line Treatment Second Line Treatment Treatment Outcome Treatment in France - HBV First Line Treatment Second Line Treatment Treatment Outcome Treatment in France - HCV First Line Treatment Second Line Treatment Treatment Outcome Treatment in Germany - HBV First Line Treatment Second Line Treatment Treatment Outcome Treatment in Germany - HCV First Line Treatment Second Line Treatment Treatment Outcome Treatment in Italy - HBV First Line Treatment Second Line Treatment Treatment Outcome Treatment in Italy - HCV First Line Treatment Second Line Treatment Treatment Outcome Treatment in Spain - HBV First Line Treatment Second Line Treatment Treatment Outcome Treatment in Spain - HCV First Line Treatment Second Line Treatment Treatment Outcome Treatment in the UK - HBV First Line Treatment Second Line Treatment Treatment Outcome Treatment in the UK - HCV First Line Treatment Second Line Treatment Treatment Outcome ANALYST INSIGHT Introduction Key Impacts on the Future Treatment of HBV Unmet Needs Health Economics The Continued Growth of the Developed World Market HIV and HDV Coinfection Conclusions - The Future of HBV Therapy Key Impacts on the Future Treatment of HCV Unmet Needs Health Economics Expansion of Treatment into New Product Sectors HIV Coinfection Conclusions - The Future of HCV Therapy APPENDIX Datamonitor's Infectious Disease Business Unit Contributing experts Research Methodology Bibliography Key Links Used for this Report Future Reading and Contacts © Datamonitor 2002. All Rights Reserved. AbstractTreatment Algorithm 2002:Hepatitis B and C is an analysis of the treatment patterns of hepatitis B (HBV) and hepatitis C (HCV) infection, in seven of the worlds major markets, namely the US, Japan, France, Germany, Italy Spain and the UK. The report is based on extensive primary physician research across these regions, and validated through secondary research, with NGOs, government agencies and clinical and research journals. Structure of report: The report is broken down into 4 sections, as described below: * Clinical overview - Complete epidemiological analysis, by incidence and prevalence for the seven major markets. The patient group is analyzed and split by diagnosis and treatment. * Presentation, Screening and Diagnosis - provides a breakdown of physician types involved in presentation, diagnosis and treatment. Screening programs and diagnostic guidelines are analyzed for each country. * Global Treatment patterns - Breakdown of patient share between first line therapy treatment, including dosage amount, frequency and length of therapy. Response and relapse rates to each therapy are provided, along with a further breakdown of second line treatment. Analysis of global treatment patterns and variations are followed by a more in depth view of each of the seven major markets. * Analyst insight - The key impacts on future treatment of HBV and HCV, both from a physician perspective, and from Datamonitors viewpoint. Unmet needs in the treatment of hepatitis are identified, and the health economics of both diseases are discussed, specifically the growth of the diseased population in the major markets, the impact of vaccination on the progression of HBV disease, the increasing significance of HIV comorbidity and the prospective for prophylactic and therapeutic vaccine development for HCV infection.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||